{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-324972","form_type":"8-K","ticker":"EVMN","cik":"0002044725","company_name":"Evommune, Inc.","filed_at":"2026-07-30T12:01:01+00:00","discovered_at":"2026-07-30T12:05:00.362431+00:00","generated_at":"2026-07-30T12:05:20.497771+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Evommune doses first patient in Phase 2b trial of EVO756 for migraine prophylaxis","bullets":["First patient dosed in Phase 2b trial of MRGPRX2 inhibitor EVO756 for migraine prophylaxis.","Global, randomized, double-blind, placebo-controlled, dose-ranging trial with ~330 patients over 12 weeks.","Top-line data expected in 2027; daily doses up to 100 mg being tested.","EVO756 designed to inhibit three key neuropeptides (PACAP, VIP, Substance P) via MRGPRX2.","Primary endpoint: mean change from baseline in monthly migraine days (MMD)."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-324972","json":"https://secwatch.observer/filing/0001193125-26-324972.json","markdown":"https://secwatch.observer/filing/0001193125-26-324972.md","text":"https://secwatch.observer/filing/0001193125-26-324972.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/2044725/000119312526324972/0001193125-26-324972-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/2044725/000119312526324972/evmn-20260731.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-07-30T12:05:20.497771+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}